Cargando…
Ventricular conduction is a marker for arrhythmic risk in overlap sodium channel disease
FUNDING ACKNOWLEDGEMENTS: Type of funding sources: Public Institution(s). Main funding source(s): National Institute of Health Research St George's, University of London BACKGROUND: SCN5A-E1784K (c.5350G>A) is the most common variant associated with the LQT3 long QT syndrome (LQTS) and Bruga...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10207071/ http://dx.doi.org/10.1093/europace/euad122.280 |
_version_ | 1785046368507658240 |
---|---|
author | Wijeyeratne, Y Tanck, M W Mckeown, P P Probst, V Crotti, L Page, S Galvin, J Petzer, E Horie, M Roden, D Veltmann, C Makita, N Aiba, T Ackerman, M J Behr, E R |
author_facet | Wijeyeratne, Y Tanck, M W Mckeown, P P Probst, V Crotti, L Page, S Galvin, J Petzer, E Horie, M Roden, D Veltmann, C Makita, N Aiba, T Ackerman, M J Behr, E R |
author_sort | Wijeyeratne, Y |
collection | PubMed |
description | FUNDING ACKNOWLEDGEMENTS: Type of funding sources: Public Institution(s). Main funding source(s): National Institute of Health Research St George's, University of London BACKGROUND: SCN5A-E1784K (c.5350G>A) is the most common variant associated with the LQT3 long QT syndrome (LQTS) and Brugada syndrome (BrS). It exhibits incomplete penetrance and can manifest variably as a mixed clinical phenotype of LQTS, BrS and/or conduction disorders (1-4). This presents a challenge for risk stratification and optimal management. We aimed to describe the clinical characteristics and risk markers in a large, well characterised international cohort of SCN5A-E1784K subjects and identify demographic and/or ECG parameters associated with event free survival. METHODS: Comprehensive clinical data, including initial presentation and follow-up data, were collected from SCN5A-E1784K subjects. Outcome ‘events’ included sudden death, aborted cardiac arrest, and documented VF or VT or arrhythmic syncope. ‘Lethal events’ included sudden death, aborted cardiac arrest or documented VF or VT. Associations between clinical characteristics and event free survival were investigated using Cox proportional hazard regression models. RESULTS: SCN5A-E1784K subjects (n=231) were recruited from 16 centres. Median follow up was 24.9 years (15.2 - 43.3) and 45 individuals (19%) experienced an event. Lethal events were observed in 14 subjects (6%). Figure 1 shows event (A) and lethal event (B) free survival in SCN5A-E1784K subjects. Higher QRS duration (corrected for age) was associated with shorter event-free interval. QRS duration was the only characteristic associated with increased risk with a hazard ratio (HR) of 1.04 or 1.05 per ms for events and lethal events, respectively. The observed survival for events and lethal events for QRS tertiles are shown in Figure 2. Discussion Ventricular myocardial conduction, as evidenced by QRS duration, appears to play a role in the risk of arrhythmic events in patients with SCN5A-E1784K. Corrected QT interval and BrS phenotype were, however, not associated with risk. This provides an important opportunity for the personalisation of risk stratification of these patients, whose management can otherwise be very challenging. Figures [Figure: see text] [Figure: see text] |
format | Online Article Text |
id | pubmed-10207071 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-102070712023-05-25 Ventricular conduction is a marker for arrhythmic risk in overlap sodium channel disease Wijeyeratne, Y Tanck, M W Mckeown, P P Probst, V Crotti, L Page, S Galvin, J Petzer, E Horie, M Roden, D Veltmann, C Makita, N Aiba, T Ackerman, M J Behr, E R Europace 13.2 - Epidemiology, Prognosis, Outcome FUNDING ACKNOWLEDGEMENTS: Type of funding sources: Public Institution(s). Main funding source(s): National Institute of Health Research St George's, University of London BACKGROUND: SCN5A-E1784K (c.5350G>A) is the most common variant associated with the LQT3 long QT syndrome (LQTS) and Brugada syndrome (BrS). It exhibits incomplete penetrance and can manifest variably as a mixed clinical phenotype of LQTS, BrS and/or conduction disorders (1-4). This presents a challenge for risk stratification and optimal management. We aimed to describe the clinical characteristics and risk markers in a large, well characterised international cohort of SCN5A-E1784K subjects and identify demographic and/or ECG parameters associated with event free survival. METHODS: Comprehensive clinical data, including initial presentation and follow-up data, were collected from SCN5A-E1784K subjects. Outcome ‘events’ included sudden death, aborted cardiac arrest, and documented VF or VT or arrhythmic syncope. ‘Lethal events’ included sudden death, aborted cardiac arrest or documented VF or VT. Associations between clinical characteristics and event free survival were investigated using Cox proportional hazard regression models. RESULTS: SCN5A-E1784K subjects (n=231) were recruited from 16 centres. Median follow up was 24.9 years (15.2 - 43.3) and 45 individuals (19%) experienced an event. Lethal events were observed in 14 subjects (6%). Figure 1 shows event (A) and lethal event (B) free survival in SCN5A-E1784K subjects. Higher QRS duration (corrected for age) was associated with shorter event-free interval. QRS duration was the only characteristic associated with increased risk with a hazard ratio (HR) of 1.04 or 1.05 per ms for events and lethal events, respectively. The observed survival for events and lethal events for QRS tertiles are shown in Figure 2. Discussion Ventricular myocardial conduction, as evidenced by QRS duration, appears to play a role in the risk of arrhythmic events in patients with SCN5A-E1784K. Corrected QT interval and BrS phenotype were, however, not associated with risk. This provides an important opportunity for the personalisation of risk stratification of these patients, whose management can otherwise be very challenging. Figures [Figure: see text] [Figure: see text] Oxford University Press 2023-05-24 /pmc/articles/PMC10207071/ http://dx.doi.org/10.1093/europace/euad122.280 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | 13.2 - Epidemiology, Prognosis, Outcome Wijeyeratne, Y Tanck, M W Mckeown, P P Probst, V Crotti, L Page, S Galvin, J Petzer, E Horie, M Roden, D Veltmann, C Makita, N Aiba, T Ackerman, M J Behr, E R Ventricular conduction is a marker for arrhythmic risk in overlap sodium channel disease |
title | Ventricular conduction is a marker for arrhythmic risk in overlap sodium channel disease |
title_full | Ventricular conduction is a marker for arrhythmic risk in overlap sodium channel disease |
title_fullStr | Ventricular conduction is a marker for arrhythmic risk in overlap sodium channel disease |
title_full_unstemmed | Ventricular conduction is a marker for arrhythmic risk in overlap sodium channel disease |
title_short | Ventricular conduction is a marker for arrhythmic risk in overlap sodium channel disease |
title_sort | ventricular conduction is a marker for arrhythmic risk in overlap sodium channel disease |
topic | 13.2 - Epidemiology, Prognosis, Outcome |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10207071/ http://dx.doi.org/10.1093/europace/euad122.280 |
work_keys_str_mv | AT wijeyeratney ventricularconductionisamarkerforarrhythmicriskinoverlapsodiumchanneldisease AT tanckmw ventricularconductionisamarkerforarrhythmicriskinoverlapsodiumchanneldisease AT mckeownpp ventricularconductionisamarkerforarrhythmicriskinoverlapsodiumchanneldisease AT probstv ventricularconductionisamarkerforarrhythmicriskinoverlapsodiumchanneldisease AT crottil ventricularconductionisamarkerforarrhythmicriskinoverlapsodiumchanneldisease AT pages ventricularconductionisamarkerforarrhythmicriskinoverlapsodiumchanneldisease AT galvinj ventricularconductionisamarkerforarrhythmicriskinoverlapsodiumchanneldisease AT petzere ventricularconductionisamarkerforarrhythmicriskinoverlapsodiumchanneldisease AT horiem ventricularconductionisamarkerforarrhythmicriskinoverlapsodiumchanneldisease AT rodend ventricularconductionisamarkerforarrhythmicriskinoverlapsodiumchanneldisease AT veltmannc ventricularconductionisamarkerforarrhythmicriskinoverlapsodiumchanneldisease AT makitan ventricularconductionisamarkerforarrhythmicriskinoverlapsodiumchanneldisease AT aibat ventricularconductionisamarkerforarrhythmicriskinoverlapsodiumchanneldisease AT ackermanmj ventricularconductionisamarkerforarrhythmicriskinoverlapsodiumchanneldisease AT behrer ventricularconductionisamarkerforarrhythmicriskinoverlapsodiumchanneldisease |